Spyre Therapeutics Inc. (SYRE)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Spyre Therapeutics Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 17 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 98.30 $ — 95% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -100.0% failed
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 368.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 757 m net cash passed
- Operating cash flow covers the profits of the last three years 275 m failed
- Return on capital at 15% or higher, or up versus two years ago -29.1% failed
- Insiders hold at least 10% or are net buyers 5.9% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 7.6% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 11
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.95 | -3.82 – -2.29 | 0 | -48.8% | 13 |
| 12/31/2027 | -3.13 | -4.63 – -1.61 | 0 | -6.2% | 13 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.71 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.20 | – | 0 | -100.00 | – | -37 | -37 |
| 2025: Q1 | -0.74 | – | 0 | – | – | -41 | -41 |
| 2025: Q2 | -0.60 | – | 0 | – | – | -47 | -47 |
| 2025: Q3 | -0.19 | – | 0 | – | – | -37 | -37 |
| 2025: Q4 | -0.18 | – | 91 | – | -69.10 | -45 | -45 |
| 2026: Q1 | -0.20 | – | 0 | – | – | -58 | -58 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 5 | -22 | -22 | -55.40 | -19 | 63 | 67 |
| 2017 | 5 | -28 | -27 | -45.01 | -25 | 50 | 56 |
| 2018 | 4 | -45 | -44 | -53.25 | -32 | 67 | 78 |
| 2019 | 0 | -80 | -78 | -61.23 | -66 | 60 | 83 |
| 2020 | 0 | -81 | -81 | -37.89 | -76 | 140 | 162 |
| 2021 | 19 | -66 | -66 | -25.02 | -54 | 84 | 110 |
| 2022 | 2 | -85 | -84 | -24.86 | -80 | 50 | 71 |
| 2023 | 1 | -242 | -339 | -49.12 | -100 | 184 | 342 |
| 2024 | 1 | -209 | -208 | -4.42 | -157 | 518 | 608 |
| 2025 | 0 | -210 | -155 | -0.45 | -169 | 715 | 778 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Spyre Therapeutics, Inc., ein Biotechnologieunternehmen im klinischen Stadium, konzentriert sich auf die Entwicklung von Therapeutika für Patienten mit chronisch-entzündlichen Darmerkrankungen (CED) und rheumatischen Erkrankungen.
| Employees | 112 |
|---|---|
| Headquarters | Waltham, MA |
| Address | Building 23, 02453 Waltham, United States |
| Phone | 617 651 5940 |
| Website | spyre.com |
| IPO Date | 7. Apr 2016 |
| ISIN | US00773J2024 |
| Stock Split | 1:25 on 09/08/2023 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Cameron Turtle DPHIL, Ph.D. | CEO & Director | 1990 |
| Scott L. Burrows | Chief Financial Officer | 1977 |
| Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary | 1983 |
| Sheldon Sloan M.B.E., M.D. | Chief Medical Officer | 1959 |
| Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations | – |
| Brian Connolly | Chief Technical Officer | – |
| Eric McIntyre | Senior Vice President of Finance & Investor Relations | – |
| James Myers | Senior Vice President of Quality & Compliance | – |
| Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development | – |
| Melissa Cooper | Senior Vice President of People | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.